Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Eric Benevich sold 19,818 shares of the company's stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the sale, the insider now owns 40,778 shares of the company's stock, valued at $5,438,154.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Eric Benevich also recently made the following trade(s):
- On Thursday, March 14th, Eric Benevich sold 75,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $139.38, for a total value of $10,453,500.00.
Neurocrine Biosciences Stock Up 0.2 %
Shares of NBIX stock opened at $133.23 on Thursday. The business has a 50 day moving average of $136.19 and a two-hundred day moving average of $126.81. The company has a market cap of $13.26 billion, a P/E ratio of 55.05 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 52 week low of $89.04 and a 52 week high of $148.37.
Biden replacement revealed?
From Paradigm Press | Ad
A former CIA insider just announced a disturbing prediction…
Biden will withdraw as the Democrat nominee on June 13.
See his shocking evidence in this new report
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts' consensus estimates of $1.13 by $0.31. The firm had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm's revenue was up 25.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.88 EPS. Analysts expect that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current fiscal year.
Institutional Trading of Neurocrine Biosciences
Large investors have recently modified their holdings of the company. FCF Advisors LLC bought a new position in Neurocrine Biosciences in the 4th quarter worth about $1,157,000. Redhawk Wealth Advisors Inc. bought a new position in Neurocrine Biosciences in the 4th quarter worth approximately $1,245,000. HealthInvest Partners AB bought a new position in Neurocrine Biosciences in the 4th quarter worth approximately $1,662,000. Nordea Investment Management AB increased its position in Neurocrine Biosciences by 205.7% in the 3rd quarter. Nordea Investment Management AB now owns 28,591 shares of the company's stock valued at $3,279,000 after acquiring an additional 19,238 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its position in Neurocrine Biosciences by 28.3% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 69,596 shares of the company's stock worth $9,138,000 after acquiring an additional 15,367 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently commented on NBIX. Cantor Fitzgerald restated an "overweight" rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. Wells Fargo & Company raised their target price on shares of Neurocrine Biosciences from $127.00 to $140.00 and gave the company an "equal weight" rating in a research note on Thursday, February 8th. Barclays upped their price target on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 23rd. JPMorgan Chase & Co. increased their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an "overweight" rating in a report on Wednesday, March 20th. Finally, Wedbush restated an "outperform" rating and set a $147.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday. Six research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $139.67.
Check Out Our Latest Research Report on Neurocrine Biosciences
About Neurocrine Biosciences
(
Get Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
